• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir

tetano

Editor, Senior Moderator
Emerg Infect Dis. 2019 Oct 17;25(10). doi: 10.3201/eid2510.190607. [Epub ahead of print]
[h=1]Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir[SUP]1[/SUP].[/h] Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, Hodges E, Jang Y, Barnes J, Uyeki T, Davis CT, Wentworth DE, Gubareva LV.
[h=3]Abstract[/h] Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2-98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses of avian and swine origin, including viruses that have pandemic potential and those resistant to neuraminidase inhibitors.


[h=4]KEYWORDS:[/h] H7N9; United States; avian influenza; baloxavir; baloxavir marboxil; drug susceptibility; highly pathogenic viruses; influenza viruses; pandemic potential; respiratory infections; viruses; zoonoses; zoonotic influenza

PMID: 31287050 DOI: 10.3201/eid2510.190607
Free full text
 
Back
Top Bottom